ada 2025 retatrutide results 2026: TRANSCEND-T2D-1: Demonstrates Robust Reductions in HbA1c and Body Weight as Monotherapy in Type 2 Diabetes - Content Lilly's triple agonist achieves 16.8%
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12



























